A Chinese medicine composition and its preparation method and application

Abstract

The present invention relates to a Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of Chinese medicine. The Chinese medicine composition provided by the present invention comprises the following raw materials by weight: 12 parts-18 parts of Atractylodes lancea, 12 parts-18 parts of Magnolia officinalis, 9 parts-15 parts of dried orange peel, 3 parts-9 parts of Licorice, 12 parts-18 parts of Acorus calamus, 5 parts-15 parts of Chuanxiong, and 9 parts-18 parts of red peony root. The Chinese medicine composition of the present invention is cored by Atractylodes lancea, Magnolia officinalis, dried orange peel, and Licorice, and is supplemented with Acorus calamus, Chuanxiong, and red peony root, so that the Chinese medicine composition has a trend of improvement in the neurological function of patients with symptomatic cerebral artery stenosis and phlegm-dampness syndrome compared with simple western medicine treatment, can reduce the recurrence rate of patients with symptomatic cerebral artery stenosis, and has a certain protective effect on the patient's cerebral blood flow autoregulation function.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition and a preparation method and application thereof. Background Art

[0002] Stroke is an acute cerebrovascular disease caused by rupture or blockage of cerebral blood vessels, leading to local brain tissue ischemia and hypoxia, causing brain tissue damage or dysfunction. Common clinical symptoms include facial paralysis or crooked mouth, limb weakness and slurred speech. The 2016 Global Burden of Disease Report shows that stroke has become the second leading cause of death in the world, and the situation of stroke prevention and control in China is even more severe. It has now become the leading cause of premature death in the Chinese population. The treatment of ischemic stroke mainly focuses on drug thrombolysis within the time window, intravascular treatment, anti-aggregation plaque and control of high-risk factors. However, the recurrence rate of ischemic stroke in China is still at a high level. Symptomatic cerebral artery stenosis is an important cause of ischemic stroke worldwide, especially symptomatic intracranial artery stenosis is more prominent in Chinese and Asian populations. Therefore, exploring more active and effective measures to prevent and treat the occurrence and development of symptomatic cerebral artery stenosis is particularly necessary to improve the prognosis of ischemic stroke population and reduce the disease burden caused by stroke.

[0003] At present, the recurrence rate of ischemic stroke in my country is still at a high level. Symptomatic cerebral artery stenosis is one of the main risk factors for ischemic stroke, among which intracranial artery stenosis is particularly common in the Chinese population. Intensive medical treatment and endovascular treatment are one of the important treatments for symptomatic cerebral artery stenosis. However, conventional anti-plaque therapy cannot eliminate the recurrence of all patients and the adverse prognosis such as lumen and stent restenosis after endovascular treatment. This makes the current treatment of symptomatic intracranial artery stenosis still face many difficulties and challenges. Therefore, it is very necessary to develop new complementary and alternative drug solutions. Summary of the invention

[0004] The purpose of the present invention is to overcome the problems existing in the above-mentioned prior art and to provide a Chinese medicine composition and a preparation method and application thereof.

[0005] The present invention is achieved through the following technical solutions:

[0006] In a first aspect, the present invention provides a traditional Chinese medicine composition, comprising the following raw materials, by weight: 12-18 parts of Atractylodes lancea, 12-18 parts of Magnolia officinalis, 9-15 parts of Citrus reticulata, 3-9 parts of Licorice, 12-18 parts of Acorus calamus, 5-15 parts of Ligusticum chuanxiong, and 9-18 parts of Paeonia lactiflora.

[0007] In the Chinese medicine composition of the present invention, Atractylodes macrocephala has a pungent and bitter taste and is warm in nature. It is regulated by the spleen, stomach and liver meridians, has the effects of drying dampness and strengthening the spleen, dispelling wind and dispersing cold, and can treat dampness blocking the middle jiao and phlegm and dampness stagnation. Magnolia officinalis has a bitter and pungent taste and is warm in nature. It is regulated by the spleen, stomach, lung and large intestine meridians, can dry dampness and eliminate phlegm, and relieve qi and dissipate fullness; Acorus calamus has a pungent and bitter taste and is warm in nature. It is regulated by the heart and stomach meridians, can open the mind and resolve phlegm, wake up the mind and improve intelligence, and remove dampness and stimulate appetite; the two are used in combination, promote each other, and assist the monarch drug in increasing the effect of drying dampness and resolving phlegm, and are the ministerial drugs. Chuanxiong has a pungent taste and is warm in nature. It is regulated by the liver, gallbladder and pericardium meridians, can promote blood circulation and qi, dispel wind and relieve pain; Paeonia lactiflora has a bitter taste and is cold in nature. It can clear away heat and cool blood, disperse blood stasis and relieve pain, and is good at "stagnation in blood circulation"; the two are used in combination, cold and warm, cooperate with each other, enhance the power of promoting blood circulation, and can be used to treat blood stasis caused by any reason, and are the ministerial drugs. Tangerine peel, bitter and pungent, warm in nature, enters the lung and spleen meridians, can regulate qi and strengthen the spleen, dry dampness and resolve phlegm; used for middle-jiao cold dampness spleen and stomach qi stagnation, to help the power of Atractylodes macrocephala and Magnolia officinalis, as an adjuvant. Licorice, sweet in taste, flat in nature, enters the heart, lung, spleen, stomach meridians, used to reconcile various medicines, as a guiding medicine. The Chinese medicine composition of the present invention is cored with Atractylodes macrocephala, Magnolia officinalis, Tangerine peel, and Licorice, and is supplemented with Acorus calamus, Chuanxiong and Paeonia lactiflora, so that the Chinese medicine composition has a trend of improvement in the neurological function of patients with symptomatic cerebral artery stenosis and phlegm-dampness syndrome compared with simple Western medicine treatment, can reduce the recurrence rate of patients with symptomatic cerebral artery stenosis, and has a certain protective effect on the patient's cerebral blood flow autoregulation function.

[0008] As a preferred embodiment of the Chinese medicine composition of the present invention, the Chinese medicine composition comprises the following raw materials in parts by weight: 15 parts of Atractylodes lancea, 15 parts of Magnolia officinalis, 12 parts of Citrus reticulata, 6 parts of Licorice, 15 parts of Acorus calamus, 10 parts of Ligusticum chuanxiong, and 15 parts of Paeonia lactiflora.

[0009] In a second aspect, the present invention provides a method for preparing the Chinese medicine composition, comprising the following steps: mixing Atractylodes lancea, Magnolia officinalis, Tangerine peel, Licorice, Acorus calamus, Ligusticum chuanxiong and Paeonia lactiflora according to the stated weight proportions, boiling with water for extraction, collecting volatile oil, filtering the extract, concentrating, drying, wet granulating, and mixing evenly with the obtained volatile oil to obtain the Chinese medicine composition.

[0010] Preferably, the wet granulation method is: crushing the dry extract obtained after drying to make a soft material, shaking granulation, boiling drying, and obtaining granules.

[0011] Preferably, the mass ratio of water to solid material in the boiling process is (8-10):1.

[0012] Preferably, the water is added and boiled for 3 times, and the amount of water added each time is 8 times, 7 times, and 7 times the mass of the solid material, respectively; the extraction time each time is 1.5 hours, 1 hour, and 1 hour, respectively. More preferably, the solid material is soaked for 30 minutes before each boiling.

[0013] Preferably, the filtration is carried out using a 200-mesh filter; the concentration is carried out at a temperature below 70° C.; the drying is vacuum drying at a temperature not exceeding 70° C.; and the specific gravity of the extract after concentration is not less than 1.30.

[0014] In a third aspect, the present invention provides a method for preparing the Chinese medicine composition, comprising the following steps:

[0015] (1) boiling atractylodes, magnolia bark, tangerine peel, liquorice, calamus, ligusticum, red peony root and red peony root respectively, filtering, concentrating the filtrate into a clear paste, spray drying, sieving and mixing to obtain atractylodes extract, magnolia bark extract, tangerine peel extract, liquorice extract, calamus extract, ligusticum extract and red peony root extract respectively;

[0016] (2) The extracts obtained in step (1) are mixed uniformly, dried to form a dry extract, and the obtained dry extract is dry-granulated to form granules to obtain a Chinese medicine composition.

[0017] As a preferred embodiment of the method for preparing the traditional Chinese medicine composition of the present invention, in the step (1), the specific gravity of the clear paste is not less than 1.3; and the mass ratio of water to solid material in the decoction is (8-10):1.

[0018] Preferably, in step (2), the mesh size of the particles is 200 mesh.

[0019] Preferably, in step (1), the number of times of decocting with water is 3 times, and the method of decocting with water is first soaking for 30 minutes, and then decocting for 1.5 hours, 1 hour, and 1 hour in sequence.

[0020] In a fourth aspect, the present invention provides a Chinese medicine compound preparation comprising the Chinese medicine composition.

[0021] The Chinese medicine composition of the invention can be prepared into a Chinese medicine compound preparation and applied as a therapeutic drug for people suffering from symptomatic intracranial artery stenosis.

[0022] As a preferred embodiment of the Chinese medicine compound preparation of the present invention, the dosage form of the Chinese medicine compound preparation is tablets, pills, capsules, granules, powders or oral liquids.

[0023] As a preferred embodiment of the Chinese medicine compound preparation of the present invention, the Chinese medicine compound preparation further includes medically acceptable excipients.

[0024] Preferably, the auxiliary material includes at least one of a filler, a lubricant, a dispersant, a wetting agent, a binder, an antioxidant, and a preservative.

[0025] In a fifth aspect, the present invention provides use of the Chinese medicine composition in preparing a drug for treating symptomatic intracranial artery stenosis.

[0026] The Chinese medicine composition of the present invention has a certain therapeutic effect in treating symptomatic intracranial artery stenosis through clinical efficacy verification, and can be used in the preparation of drugs for treating symptomatic intracranial artery stenosis, providing a new supplementary alternative for treating such diseases.

[0027] Preferably, the symptomatic intracranial artery stenosis is ischemic stroke and / or transient ischemic event occurring in the past 3 months, accompanied by intracranial artery stenosis (stenosis rate 50% to 99%).

[0028] Preferably, the lesion of symptomatic intracranial artery stenosis is located in the territory supplied by the responsible artery or the symptoms of transient ischemic attack match the neurological function of the brain tissue in the territory supplied by the responsible artery.

[0029] The present invention has the following beneficial effects: the present invention mainly develops a Chinese medicine composition that can reduce the risk of recurrence and restenosis of blood vessels for people with symptomatic intracranial artery stenosis, and provides a new supplementary alternative for treating such diseases. The Chinese medicine composition of the present invention has been found to have a trend of improvement in the neurological function of patients with symptomatic cerebral artery stenosis and phlegm-dampness syndrome compared with simple Western medicine treatment in the treatment of patients with symptomatic cerebral artery stenosis, can reduce the recurrence rate of patients with symptomatic cerebral artery stenosis, and has a certain protective effect on the patient's dynamic cerebral blood flow autoregulation ability. In addition, only a few gastrointestinal adverse reactions occur during use, and there are no obvious symptoms of drug damage, indicating that the Chinese medicine composition of the present invention has good safety. The Chinese medicine composition of the present invention provides reference value for the treatment of symptomatic cerebral artery stenosis with traditional Chinese medicine, and is worthy of clinical promotion and application. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The Venn diagram of each raw material of the Chinese medicine composition of the present invention;

[0031] Figure 2 This is a KEGG analysis diagram of targets related to the treatment of symptomatic cerebral artery stenosis by the Chinese medicine composition of the present invention. DETAILED DESCRIPTION

[0032] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. It should be understood by those skilled in the art that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0033] Unless otherwise specified, the experimental methods used in the examples are all conventional methods; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial channels.

[0034] Example 1

[0035] A Chinese medicine composition comprises the following raw materials by weight: 15g of Atractylodes lancea, 15g of Magnolia officinalis, 12g of dried tangerine peel, 6g of Licorice, 15g of Acorus calamus, 10g of Ligusticum chuanxiong and 15g of Paeonia lactiflora.

[0036] The preparation method of the Chinese medicine composition described in this embodiment comprises the following steps: mixing Atractylodes lancea, Magnolia officinalis, Tangerine peel, Licorice, Acorus calamus, Ligusticum chuanxiong and Paeonia lactiflora according to the weight, adding water and boiling for extraction three times, with the amount of water added (8 times, 7 times, 7 times), and the extraction time (first soaking for 30 minutes, 1.5 hours, 1 hour, 1 hour), and collecting volatile oil by refluxing at the same time, filtering the three extracts through a 200-mesh filter, concentrating under reduced pressure (below 70° C.) to form an extract with a specific gravity of more than 1.30, and drying in a vacuum drying oven (below 70° C.) to form a dry extract; crushing the dry extract and adding an appropriate amount of ethanol as a wetting agent to make a soft material, granulating by swinging, boiling drying, spraying the collected volatile oil into the dry particles, and mixing to obtain the Chinese medicine composition.

[0037] Example 2

[0038] A Chinese medicine composition comprises the following raw materials by weight: 12g of Atractylodes lancea, 12g of Magnolia officinalis, 9g of Tangerine peel, 3g of Licorice, 12g of Acorus calamus, 5g of Chuanxiong, and 9g of Red Peony Root.

[0039] The preparation method of the Chinese medicine composition described in this embodiment comprises the following steps: mixing Atractylodes lancea, Magnolia officinalis, Tangerine peel, Licorice, Acorus calamus, Ligusticum chuanxiong and Paeonia lactiflora according to the weight, adding water and boiling for extraction three times, with the amount of water added (8 times, 7 times, 7 times), and the extraction time (first soaking for 30 minutes, 1.5 hours, 1 hour, 1 hour), and collecting volatile oil by refluxing at the same time, filtering the three extracts through a 200-mesh filter, concentrating under reduced pressure (below 70° C.) to form an extract with a specific gravity of more than 1.30, and drying in a vacuum drying oven (below 70° C.) to form a dry extract; crushing the dry extract and adding an appropriate amount of ethanol as a wetting agent to make a soft material, granulating by swinging, boiling drying, spraying the collected volatile oil into the dry particles, and mixing to obtain the Chinese medicine composition.

[0040] Example 3

[0041] A Chinese medicine composition comprises the following raw materials by weight: 18g of Atractylodes lancea, 18g of Magnolia officinalis, 15g of Tangerine peel, 9g of Licorice, 18g of Acorus calamus, 15g of Ligusticum chuanxiong and 18g of Red Peony Root.

[0042] The preparation method of the Chinese medicine composition described in this embodiment comprises the following steps: mixing Atractylodes lancea, Magnolia officinalis, Tangerine peel, Licorice, Acorus calamus, Ligusticum chuanxiong and Paeonia lactiflora according to the weight, adding water and boiling for extraction three times, with the amount of water added (8 times, 7 times, 7 times), and the extraction time (first soaking for 30 minutes, 1.5 hours, 1 hour, 1 hour), and collecting volatile oil by refluxing at the same time, filtering the three extracts through a 200-mesh filter, concentrating under reduced pressure (below 70° C.) to form an extract with a specific gravity of more than 1.30, and drying in a vacuum drying oven (below 70° C.) to form a dry extract; crushing the dry extract and adding an appropriate amount of ethanol as a wetting agent to make a soft material, granulating by swinging, boiling drying, spraying the collected volatile oil into the dry particles, and mixing to obtain the Chinese medicine composition.

[0043] Effect example

[0044] 1. Clinical trials for the treatment of symptomatic intracranial (cerebral) artery stenosis

[0045] Clinical research plan: A prospective non-randomized controlled method was used to enroll 60 patients with symptomatic cerebral artery stenosis and phlegm-dampness syndrome who met the inclusion and exclusion criteria of the subject and were continuously registered and admitted to the Brain Disease Center of Guangdong Provincial Hospital of Traditional Chinese Medicine from October 2020 to November 2021. They were divided into 30 cases in the Chinese medicine treatment group and 30 cases in the control group. The control group was implemented with reference to the latest guidelines for ischemic stroke formulated by ASA, ACCP and EUSI and the "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018". The treatment group was added with the Chinese medicine composition of Example 1 of the present invention on the basis of the control group (oral, three times a day, 1 bag each time). The treatment cycle of the two groups was 90 days, and the general information of the subjects was recorded to evaluate the clinical efficacy and safety before and after treatment for 90 days. During the study, 58 cases completed 90 days of clinical follow-up, and 2 cases dropped out of the treatment group because the medication did not reach 80%.

[0046] After treatment, the facial function of the two groups of patients was improved compared with that before the onset of the disease. In the mRS grading, with mRS≤1 as the standard, it was found that the proportion of patients with mRS≤1 in the treatment group was higher than that in the control group, with a P value of 0.07, indicating that after treatment with the Chinese medicine composition of Example 1, the neurological function of patients with symptomatic cerebral artery stenosis was better improved, and the study had a certain trend, as shown in Table 1 for details.

[0047] Table 1 Comparison of neurological function scores between the two groups after 90 days of treatment

[0048]

[0049] After 90 days of treatment, the SS-QOL scale scores of the two groups were 227.11±14.81 in the treatment group and 219.33±23.01 in the control group, with no significant difference (P>0.05). In the 12 areas of the SS-QOL scale, the study showed that after treatment, the patients in the treatment group had better improvement in family roles than those in the control group, with a statistically significant difference (P<0.05), as shown in Table 2.

[0050] Table 2 SS-QOL scores of the two groups after 90 days of treatment

[0051]

[0052] After 90 days of treatment, the low-frequency phase difference (right side) of the treatment group was higher than that of the control group, and the difference was statistically significant, indicating that the dCA function of the treatment group was better than that of the control group; there was no statistically significant difference between the other groups in the parameters of cerebral blood flow autoregulation (gain, phase difference) (P>0.05). Moreover, compared with the baseline, although the low-frequency phase difference between the two groups indicated that the cerebral blood flow regulation function was still impaired, the degree of damage in the control group was more severe than before, as shown in Table 3.

[0053] Table 3 Comparison of cerebral blood flow autoregulation parameters between the two groups after 90 days of treatment

[0054]

[0055] Evaluation of recurrent events: In this study, one patient in the treatment group had a TIA event during the trial, with a recurrence rate of 3.57% (1 / 28). In the control group, one patient had an IS recurrence event and one patient had a TIA event during the trial, with a recurrence rate of 6.67% (2 / 30).

[0056] Safety evaluation: During this trial, one patient in the Chinese medicine treatment group had rotten stools and one patient had dry stools. These were symptoms that occurred after taking the medicine and did not affect the patient's daily life. The patient said that he could tolerate the clinical trial and continued to undergo the clinical trial. The symptoms were relieved and healed after follow-up observation. No obvious drug damage was found in the blood routine tests and liver and kidney functions of the two groups of patients. Only a few gastrointestinal adverse reactions occurred during the use of the Chinese medicine composition of the present invention, and there were no obvious symptoms of drug damage, indicating the safety of the prescription.

[0057] Clinical trials evaluate mRS, BI, stroke TCM symptom score, stroke-specific quality of life, dynamic cerebral blood flow autoregulation ability and related recurrence events before and after treatment for 90 days. The results show that the Chinese medicine composition of the present invention has a trend of improvement in the neurological function of patients with symptomatic cerebral artery stenosis and phlegm-dampness syndrome compared with simple Western medicine treatment, can reduce the recurrence rate of patients with symptomatic cerebral artery stenosis, and has a certain protective effect on the dynamic cerebral blood flow autoregulation ability of patients. In addition, only a few gastrointestinal adverse reactions occur during the use of the Chinese medicine composition of the present invention, and there are no obvious symptoms of drug damage, indicating the safety of the composition.

[0058] 2. Potential Mechanisms of Chinese Medicine Compositions

[0059] The present invention obtains a total of 15 components of Atractylodes lancea from the BATMAN-TCM platform, including atractylodesone, atractylodesin, β-eudesmol, etc.; 42 components of Magnolia officinalis, including magnolol, magnolin, magnolamine, etc.; 32 components of Citrus reticulata, including γ-terpinene, hesperidin, etc.; 12 components of Acorus tatarinowii, including β-asarone, eugenol, etc.; 91 components of Ligusticum chuanxiong, including ligustrazine, ligustrin, ferulic acid, etc.; 9 components of Paeonia lactiflora, including paeoniflorin, paeoniflorin, paeoniflorin, etc.; 75 components of Licorice, including glycyrrhizic acid, glycyrrhizic polysaccharide, etc. In terms of component prediction targets, a total of 312 predicted targets were obtained for Atractylodes lancea, 904 predicted targets for Magnolia officinalis, 600 predicted targets for Citrus reticulata, 526 predicted targets for Acorus calamus, 956 predicted targets for Ligusticum chuanxiong, 62 predicted targets for Paeonia lactiflora, and 685 predicted targets for Licorice. After removing duplicate targets, 1580 targets of the Chinese medicine prescription for "removing dampness and resolving phlegm" were finally obtained. Figure 1 .

[0060] The PPI network was topologically analyzed by the Network Analysis function to obtain the degree, betweenness centrality and closeness centrality of each node, and the Top 20 targets were screened according to the degree values. They were the key targets for the Chinese medicine composition of the present invention to treat symptomatic cerebral artery stenosis, including interleukin 6, AKT serine / threonine kinase 1, albumin, tumor necrosis factor CC-Motif chemokine ligand 2, interleukin 1β and other targets, as shown in Table 4 for details.

[0061] Table 4 Key targets of the Chinese medicine composition of the present invention for treating symptomatic cerebral artery stenosis

[0062]

[0063]

[0064] In terms of pathway enrichment, there were 79 pathways with P < 0.01. Combined with literature research reports, the potential effect pathways were visualized and analyzed using the Omicshare online tool. The results are shown in Figure 2 The results show that the mechanism of action of the Chinese medicine prescription "Qushi Huatan" in treating symptomatic cerebral artery stenosis may be closely related to the HIF-1 signaling pathway, FoxO signaling pathway, T cell receptor signaling pathway, Rap1 signaling pathway, Toll-like receptor signaling pathway, cell apoptosis, estrogen / prolactin signaling pathway, VEGF signaling pathway, and thyroid hormone signaling pathway.

[0065] The present invention utilizes the BATMAN-TCM platform to collect chemical components and target genes of a Chinese medicine composition (Atractylodes lancea, Magnolia officinalis, Tangerine peel, Licorice, Acorus calamus, Ligusticum chuanxiong, and Paeonia lactiflora); obtains target genes of ischemic stroke and atherosclerosis-related diseases through DisGeNET, Genecards, and HPO databases; selects the intersection of the two as candidate targets and uploads them to the String database to obtain the target protein interaction relationship; calculates network eigenvalues ​​to screen key targets of the Chinese medicine composition for treating atherosclerotic stroke; and uses DAVID and Metascape analysis platforms to perform gene function, pathway enrichment, and clustering analysis on key targets.

[0066] Network pharmacology studies obtained 15 potential active ingredients, including Atractylodes macrocephala, 42 Magnolia officinalis, 32 Citrus reticulata, 75 Licorice, 12 Acorus calamus, 91 Ligusticum chuanxiong, and 9 Paeonia lactiflora, with a total of 1580 predicted targets, 926 targets for ischemic stroke, and 1340 targets for atherosclerosis. Through network topology feature analysis, key targets were screened out, including IL6, AKT1, ALB, TNF, CCL2, IL1B, PTGS2, MAPK1, TP53, and NOS3. Further GO and KEGG enrichment analysis showed that it acts on the HIF-1 signaling pathway, FoxO signaling pathway, T cell receptor signaling pathway, Rap1 signaling pathway, Toll-like receptor signaling pathway, and estrogen / prolactin signaling pathway. The potential effect mechanism of the Chinese medicine combination in the treatment of atherosclerotic stroke was revealed at the molecular mechanism level, and its mechanism is mostly related to biological factors such as inflammatory immune response, cell apoptosis, gene regulation, hypoxia response, and vascular endothelial function.

[0067] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A Chinese medicine composition for treating symptomatic intracranial artery stenosis, characterized in that: The invention is prepared from the following raw materials by weight: 12-18 parts of Atractylodes lancea, 12-18 parts of Magnolia officinalis, 9-15 parts of Tangerine peel, 3-9 parts of Licorice, 12-18 parts of Acorus calamus, 5-15 parts of Chuanxiong and 9-18 parts of Red Peony Root.

2. The Chinese medicine composition for treating symptomatic intracranial artery stenosis according to claim 1, characterized in that: The invention is prepared from the following raw materials by weight: 15 parts of atractylodes, 15 parts of magnolia bark, 12 parts of dried tangerine peel, 6 parts of liquorice, 15 parts of calamus, 10 parts of ligusticum chuanxiong and 15 parts of red peony root.

3. A method for preparing a Chinese medicine composition for treating symptomatic intracranial artery stenosis according to claim 1 or 2, characterized in that: The following steps are involved: Atractylodes, Magnolia officinalis, Tangerine peel, Licorice, Acorus calamus, Ligusticum chuanxiong and Paeonia lactiflora are mixed according to the weight proportions, and then boiled with water for extraction, and volatile oil is collected. The extract is filtered, concentrated, dried, wet granulated, and mixed with the obtained volatile oil to obtain a traditional Chinese medicine composition.

4. A method for preparing the Chinese medicine composition for treating symptomatic intracranial artery stenosis according to claim 1 or 2, characterized in that: The following steps are involved: (1) Add water to decoct Atractylodes lancea, Magnolia officinalis, Tangerine peel, Licorice root, Acorus calamus, Ligusticum chuanxiong and Paeonia lactiflora, respectively, filter, concentrate the filtrate into a clear paste, spray dry, sieve and mix, and obtain Atractylodes lancea extract, Magnolia officinalis extract, Tangerine peel extract, Licorice root extract, Acorus calamus extract, Ligusticum chuanxiong extract and Paeonia lactiflora extract, respectively; (2) The extracts obtained in step (1) are mixed uniformly, dried to form a dry extract, and the dry extract is dry-granulated to form granules to obtain a Chinese medicine composition.

5. A Chinese medicine compound preparation prepared from the Chinese medicine composition for treating symptomatic intracranial artery stenosis according to claim 1 or 2.

6. The Chinese medicinal compound preparation according to claim 5, characterized in that: The dosage form of the Chinese medicine compound preparation is tablets, pills, capsules, granules, powders or oral liquids.

7. The Chinese medicinal compound preparation according to claim 5, characterized in that: The traditional Chinese medicine compound preparation also includes medically acceptable auxiliary materials.

8. The Chinese medicinal compound preparation according to claim 7, characterized in that: The auxiliary materials include at least one of fillers, lubricants, dispersants, wetting agents, adhesives, antioxidants and preservatives.

9. Use of the Chinese medicine composition for treating symptomatic intracranial artery stenosis according to claim 1 or 2 in preparing a drug for treating symptomatic intracranial artery stenosis.

10. The use according to claim 9, characterized in that: The symptomatic intracranial artery stenosis is an ischemic stroke and / or transient ischemic event occurring in the past 3 months, accompanied by intracranial artery stenosis.

Images